Infex Therapeutics presents new Phase IIa data for RESP-X at ERS Congress 2026, providing further evidence on exploratory efficacy endpoints supporting progression to later stage development
Pa-positive NCFB patients experienced a significant reduction in annualised…
Infex Therapeutics to present new RESP-X Phase IIa data in late-breaking session at ERS Congress 2026
Presentation will provide additional analysis from the Phase IIa study of…
Infex Therapeutics written submission to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB)
Below is the text that Infex Therapeutics submitted to the Presidential…
Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
Alderley Park, Cheshire, U.K. – 12 May 2026, Infex Therapeutics, a leading…
World AMR Awareness Week 2025
This World AMR Awareness Week, we're proud to be celebrating our collaboration…
Infex invites you to Alderley Park's 10th Anniversary SciTech Extravaganza
Saturday 14 September, 10:00am - 3:00pm Come and join us in Glasshouse at…
Infex webinar - broader pipeline and growth strategy
On 9th May 2024, Infex Therapeutics held a live webinar, to update on the…
Infex CSO invited to speak at GARDP REVIVE Webinar
On 27th June, Dr Victoria Savage, Chief Scientific Officer for Infex…
Infex to present webinar on broader pipeline and growth strategy
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
BioTrinity, 28-29th April 2020
London Link: biotrinity.com We’re attending BioTrinity 2020 in London,…